CorMedix Inc.
CRMDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CorMedix Inc. focuses on Biotechnology services and products. CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. With a market capitalization of $657.1M, it sits in small-cap territory. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Market Cap
$657.1M
Beta
1.50
P/E (TTM)
3.87
P/E (Fwd)
24.09
EPS (TTM)
$2.18
EPS (Fwd)
$0.35
ROE
54.9%
ROA
24.6%
Cash
$256.7M
Total Debt
$147.5M
Free CF
$178.1M
52W Change
-35.3%
Annual Financials
Cash vs Debt
Where CRMD stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, CRMD finished 7.55% above its 150-day moving average ($7.68) and 0.48% below its 200-day moving average ($8.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRMD overbought or oversold?
At the September 1, 2026 close, CRMD's RSI(14) was 62.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CorMedix Inc. holds $256.7M in cash against $147.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $178.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 54.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 24.6% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $191K to $311.7M.
A beta of 1.50 means CRMD is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CorMedix Inc.'s trajectory.